<DOC>
	<DOCNO>NCT00922116</DOCNO>
	<brief_summary>This single arm study ass efficacy , safety tolerability monthly administration subcutaneous Mircera maintenance hemoglobin level patient chronic renal anemia dialysis.Patients receive sc Mircera start dose 100 , 120 , 200 360 microgram every 4 week , calculate last weekly dose ESA previously administer . Subsequent dos adjust maintain hemoglobin level within target range . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Once Monthly Subcutaneous Mircera Patients With Chronic Renal Anemia Not Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic renal anemia ; continuous maintenance ESA therapy dose interval previous month , change totally weekly dose . transfusion red blood cell previous 2 month ; poorly control hypertension ; significant acute chronic bleeding ; active malignant disease ( except nonmelanoma skin cancer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>